2,5-Dimethoxy-4-butylamphetamine

From Wikipedia, the free encyclopedia
(Redirected from DOBU)
Jump to navigation Jump to search

DOBU
File:DOBU.svg
Clinical data
Other namesDOBU; 2,5-Dimethoxy-4-butylamphetamine; 4-Butyl-2,5-dimethoxyamphetamine
Routes of
administration
Oral[1][2][3]
Drug classSerotonin 5-HT2 receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Duration of action"Very long"[2]
Identifiers
  • 1-(4-butyl-2,5-dimethoxyphenyl)propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC15H25NO2
Molar mass251.370 g·mol−1
3D model (JSmol)
  • C1(=CC(=C(C=C1CC(C)N)OC)CCCC)OC
  • InChI=1S/C15H25NO2/c1-5-6-7-12-9-15(18-4)13(8-11(2)16)10-14(12)17-3/h9-11H,5-8,16H2,1-4H3 checkY
  • Key:NGVDYAULSQKEGW-UHFFFAOYSA-N checkY
  (verify)

2,5-Dimethoxy-4-butylamphetamine (DOBU) is a psychedelic drug of the phenethylamine, amphetamine, and DOx families related to DOM.[2][1][4] It is the derivative of DOM in which the methyl group at the 4 position has been replaced with a butyl group.[2] The drug is taken orally.[1][2][3]

It acts as a serotonin receptor agonist, including of the serotonin 5-HT2A receptor.[4] The drug produces psychedelic-like effects in animals.[4]

DOBU was first described in the literature by Alexander Shulgin in 1970.[5] Subsequently, it was described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).[2]

Use and effects

[edit | edit source]

In his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, Alexander Shulgin and colleagues stated that doses of 1 to 3 mg orally produced clear threshold effects and that it was active at a dose of slightly more than twice that of DOM.[1][2][3] It was stated that 10 mg DOBU was required to produce hallucinogenic effects.[3] The drug's duration was listed as "very long".[2] There was limited investigation of its qualitative effects.[1] However, in PiHKAL, at the assessed doses of 2.2 mg and 2.8 mg, it was described as producing paresthesia and difficulty sleeping with few other effects.[2] The effects of higher doses of DOBU have not been described beyond them producing hallucinogenic effects.[2][3]

Interactions

[edit | edit source]

Pharmacology

[edit | edit source]

Pharmacodynamics

[edit | edit source]

Compared to shorter-chain homologues such as DOM, DOET, and DOPR, which are all potent psychedelics, DOBU has even higher affinity for the serotonin 5-HT2A receptor.[4][6] It has been found to act as a potent full agonist of the serotonin 5-HT2A and 5-HT2C receptors.[4][7][8] The drug is also a serotonin 5-HT2B receptor full agonist but with far lower potency.[4][8][7] Additional receptor interactions have also been described.[4]

DOBU fully substitutes for DOM] in rodent drug discrimination tests, albeit several-fold less potently than DOET or DOPR.[9][6][10][11] In addition, DOBU robustly induces the head-twitch response, a behavioral proxy of psychedelic-like effects, in rodents, and maximally does so about as strongly as other DOx drugs like DOM, DOET, DOPR, and DOC.[4][10] The doses at which DOBU produces peak head twitches are similar to those of DOM and DOET.[10][4]

Other effects of DOBU in rodents include hyperlocomotion at lower doses, hypolocomotion at higher doses, and hypothermia at higher doses.[4]

Pharmacokinetics

[edit | edit source]

DOBU crosses the blood–brain barrier in rodents.[4]

Chemistry

[edit | edit source]

Synthesis

[edit | edit source]

The chemical synthesis of DOBU has been described.[2]

Analogues

[edit | edit source]

Analogues of DOBU include 2,5-dimethoxyamphetamine (2,5-DMA), DOM, DOET, DOPR, and DOAM, among others.[2][4]

Isomers

[edit | edit source]

Alternative skeletal isomers of DOBU can also be produced, where the 4-(n-butyl) group of DOBU is replaced with any of the three other butyl isomers, the iso-butyl, sec-butyl and tert-butyl compounds being called DOIB, DOSB, and DOTB, respectively.[12][13][14] All are significantly less potent than DOBU, with DOIB being active at around 10–15 mg, and DOSB at 25–30 mg.[12] The most highly branched isomer DOTB was completely inactive in both animal and human trials.[12] However, it was also reported that DOTB and DOAM partially generalized to DOM in animal drug discrimination tests.[9]

File:DOIB,DOSBandDOTB.png
DOIB, DOSB, and DOTB.[12][13][14]

History

[edit | edit source]

DOBU was first described in the literature by Alexander Shulgin in 1970.[5] Subsequently, it was described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).[2]

See also

[edit | edit source]

References

[edit | edit source]
  1. ^ a b c d e Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  2. ^ a b c d e f g h i j k l m Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  3. ^ a b c d e Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  4. ^ a b c d e f g h i j k l Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  5. ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  6. ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  7. ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  8. ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  9. ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  10. ^ a b c Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  11. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  12. ^ a b c d Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  13. ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  14. ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
[edit | edit source]